• TENT5A Re-adenylation and mRNA Vaccine Efficacy

  2026-10-07

  The 2025 Nature study identifies TENT5A-mediated re-adenylation as an important post-delivery process that can stabilize therapeutic mRNAs, particularly in macrophages and other medically relevant cells. Its combination of nanopore sequencing, cellular decay analysis, and mouse immunization evidence expands mRNA vaccine research beyond initial delivery and translation to include intracellular poly(A)-tail metabolism.

• Cy5 RNA Labeling Kit: Reading RNA Condensates

  2026-10-07

  Explore how a Cy5 RNA labeling kit can support more rigorous interpretation of RNA localization, abundance, and condensation studies. This article connects HyperScribe T7 labeling with the evidence framework used to investigate SARS-CoV-2 nucleocapsid phase separation.

• DRG1, c-Myc and Lenvatinib Resistance in HCC

  2026-10-06

  A 2026 pre-proof study integrates multi-omics, tissue validation, functional assays, and xenograft evidence to position DRG1 as a driver of hepatocellular carcinoma progression and lenvatinib resistance. Its proposed HDAC2–DRG1–c-Myc regulatory axis offers a mechanistic framework for biomarker development, while the findings remain subject to validation in independent cohorts and clinical models.

• Miransertib and WecA: Reading Assay Evidence

  2026-10-06

  Miransertib provides a useful case study in how small molecules should—and should not—be interpreted in WecA research. This article examines the 2026 WecA study, its membrane-protein assay innovation, and the evidence needed before assigning compound-specific activity.

• GDC-0068 (RG7440): Evidence and Research Context

  2026-10-05

  GDC-0068, also known as RG7440, is described by APExBIO as an ATP-competitive pan-AKT inhibitor for research on PI3K/Akt/mTOR signaling. This overview separates supplier-reported potency and cancer-model findings from the stronger, spatially resolved evidence supplied by a recent Nature Chemical Biology study of mTORC1. It also examines research applications, evidence quality, interpretation limits, and the absence of direct evidence that GDC-0068 selectively controls nuclear mTORC1.

• Dextromethorphan Hydrobromide: Evidence Overview

  2026-10-05

  This overview examines dextromethorphan hydrobromide as a research probe for NMDA receptor antagonism, ion-channel modulation, excitotoxicity inhibition, and neuroprotection. It separates supplier-reported findings from peer-reviewed evidence, explains conceptual applications in neuroscience, and outlines limitations affecting interpretation, including incomplete assay provenance and the absence of supplied disease-specific clinical evidence.

• From Cy5 Probes to Translational RNA Insight

  2026-10-04

  Fluorescent RNA probes are more than detection reagents: they can connect transcript localization, probe chemistry, and translational questions about RNA delivery. This thought-leadership article examines the mechanistic role of T7 transcription and Cy5-UTP incorporation, interprets evidence from a ROS-responsive mRNA delivery study, and positions the HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit as a research-use-only tool for rigorous probe development.

• MPTP Assay Kit: Evidence and Research Context

  2026-10-03

  This source-grounded overview examines how a Calcein AM fluorescent probe is used conceptually in mitochondrial permeability transition pore detection and how that readout relates to a supplied 2026 study of Treponema pallidum-associated hepatocyte injury. It compares evidence streams, clarifies what the assay can and cannot establish, and outlines key applicability limits without providing experimental procedures.

• ZCL278: Selective Cdc42 Inhibitor Guide

  2026-10-01

  ZCL278 is a selective Cdc42 inhibitor that targets Cdc42-dependent cytoskeletal behavior, including cell motility suppression and neuronal branching inhibition. Product data support mechanistic use in cellular models, while kidney-fibrosis evidence from the cited study concerns the distinct natural compound daphnepedunin A rather than ZCL278.

• H5N1 mRNA Vaccine Protects Dairy Cows

  2026-10-01

  The reference study evaluates a hemagglutinin-based mRNA–lipid nanoparticle vaccine in high-yielding lactating dairy cows, addressing a major gap between experimental vaccine platforms and veterinary field needs. The vaccine was well tolerated, induced strong antibody responses, and protected cattle against high-dose H5N1 challenge, including substantial protection at a late time point when serum antibody levels were low.

• AZD1390 ATM Kinase Inhibitor Workflow

  2026-10-01

  Build a mechanism-led AZD1390 workflow for radiation response, checkpoint analysis, and replication-stress research. The approach distinguishes direct ATM signaling effects from broader G-quadruplex and DNA damage phenotypes in glioma and lung cancer models.

• SP2509 Workflow for LSD1-Targeted AML Research

  2026-09-30

  SP2509 enables selective interrogation of LSD1–CoREST biology, H3K4 methylation, apoptosis induction in AML cells, and differentiation-linked transcription. This workflow combines compound handling, temporal epigenetic readouts, clonogenic assays, and combination-testing logic for practical cancer epigenetics research.

• AICAR Phosphate: AMPK in Hypoxic Barriers

  2026-09-29

  AICAR phosphate (Acadesine) can serve as a mechanistic AMPK perturbation tool for connecting cellular metabolism, apoptosis, and hypoxia-induced choroid plexus barrier dysfunction. This article translates findings from a recent mouse study into a rigorous, hypothesis-driven assay strategy while separating established evidence from exploratory application.

• Rucaparib: Splicing-Linked DNA Repair in HCC

  2026-09-29

  Rucaparib and AG-014699 offer a powerful way to study PARP1-dependent DNA repair, radiation response, and spliceosome-linked vulnerabilities. This article connects SmD2-regulated BRCA1/FANC splicing with practical assay design in hepatocellular carcinoma while distinguishing established evidence from testable hypotheses.

• GDC-0941: PI3K Inhibitor Research Guide

  2026-09-28

  GDC-0941 is an orally bioavailable PI3K inhibitor that targets PI3Kα and PI3Kδ with reported 3 nM biochemical potency. Its ATP-competitive activity suppresses PIP3-dependent PI3K/Akt signaling and supports cancer cell proliferation inhibition studies in HER2-amplified and glioblastoma models.

7982 records 1/533 page Next 12345 下5页 Last page